Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of “Hold” by Brokerages

Prestige Consumer Healthcare Inc. (NYSE:PBH) has received a consensus recommendation of “Hold” from the six brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $70.75.

A number of research firms have recently issued reports on PBH. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Canaccord Genuity Group decreased their price target on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Finally, Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the transaction, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.50% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

Institutional investors have recently added to or reduced their stakes in the company. UMB Bank n.a. increased its position in Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares during the period. Bayforest Capital Ltd bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $29,000. Barrow Hanley Mewhinney & Strauss LLC grew its stake in shares of Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after acquiring an additional 283 shares in the last quarter. Geneos Wealth Management Inc. grew its stake in shares of Prestige Consumer Healthcare by 92.8% in the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares in the last quarter. Finally, Torren Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $35,000. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Price Performance

PBH opened at $48.90 on Tuesday. The stock’s fifty day simple moving average is $48.33 and its 200 day simple moving average is $57.69. Prestige Consumer Healthcare has a 1-year low of $42.62 and a 1-year high of $77.45. The stock has a market cap of $2.32 billion, a PE ratio of 12.51, a price-to-earnings-growth ratio of 1.57 and a beta of 0.35. The company has a current ratio of 3.57, a quick ratio of 2.25 and a debt-to-equity ratio of 0.54.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The company had revenue of $281.62 million for the quarter, compared to the consensus estimate of $293.64 million. During the same period last year, the firm earned $1.32 earnings per share. The company’s revenue for the quarter was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, research analysts expect that Prestige Consumer Healthcare will post 4.45 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).